Skip to main content
Clinical Trials/PACTR202107709749875
PACTR202107709749875
Recruiting
Phase 4

A Randomized Controlled Trial Assessing the Efficacy and Safety Profile of Oral Ziliv Among Patients with Hepatic Disease Attending the Gastrointestinal Clinic of the Lagos University Teaching Hospital, Idi-Araba

Zifam Pinnacle Nigeria Ltd0 sites100 target enrollmentJune 13, 2021

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Digestive System
Sponsor
Zifam Pinnacle Nigeria Ltd
Enrollment
100
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 13, 2021
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Zifam Pinnacle Nigeria Ltd

Eligibility Criteria

Inclusion Criteria

  • 1\. All consenting adults (male or female) subjects aged 18years and above.
  • 2\. All subjects with elevated alanine aminotransferase (ALT) enzyme levels of at ;least 1\.5 times upper limit normal.

Exclusion Criteria

  • 1\. Subjects less than 10years old.
  • 2\. Hepatic malignancies (primary or secondary).
  • 3\. Terminally ill patients.
  • 4\. Patients with history of advanced chronic kidney disease or on hemodialysis.
  • 5\. Patients already on other hepatic\-tonic supplements
  • 6\. Patients who refuse to give to give consent.
  • 7\. Pregnant or breastfeeding mothers.

Outcomes

Primary Outcomes

Not specified

Similar Trials